At AAN 2026, an associate professor of neurology at University of Washington discussed how delays in antiamyloid treatment initiation for early Alzheimer disease may be driven by real-world factors. [WATCH TIME: 5 minutes]
Michael Rosenbloom, MD, FAAN
Advertisement
Associate professor of neurology at UW Medicine
Articles by Michael Rosenbloom, MD, FAAN
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Donanemab Shows Durable Amyloid Clearance and Consistent Safety in Early-Start Patients
2
Masterclass at AMTRD Highlights Real-World Applications of Botulinum Toxin in Movement Disorders: Laxman Bahroo, MD
3
Subcutaneous Apomorphine Infusion Titration Reaches Optimization Without Antiemetics in Real-World PD Cohort
4
Parkinson’s Disease Impact on Daily Life and Family Burden
5